Annuncio • Jun 04
Genflow Biosciences plc, Annual General Meeting, Jun 29, 2026 Genflow Biosciences plc, Annual General Meeting, Jun 29, 2026. Location: one heddon street, w1b 4bd, london United Kingdom New Risk • Apr 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£303k). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (UK£15.0m market cap, or US$20.3m). New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£303k). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (UK£12.1m market cap, or US$16.3m). Annuncio • Apr 13
Genflow Biosciences Plc Announces International Patent Publication For Sirt6-Based Muscular Disease Program Genflow Biosciences Plc had announced the international publication of its Patent Cooperation Treaty (PCT) application, WO 2026/062177 A1, entitled "Variants of Sirtuin 6 for the Treatment of Muscular Diseases." The published PCT application relates to variants of SIRT6 for the prevention and treatment of muscular diseases, with particular focus on frailty syndrome and sarcopenia. The application describes compositions and methods involving SIRT6 variants, including nucleic acids, polypeptides, vectors and pharmaceutical compositions intended for use in muscular disease settings associated with loss of muscle mass and altered endocrine function of the muscle. This international publication represents an important milestone in Genflow's intellectual property strategy and broadens the potential protection surrounding the Company's SIRT6 platform beyond longevity and metabolic applications. By advancing patent coverage into muscular diseases, Genflow is further strengthening the proprietary foundation of its platform while opening additional potential therapeutic pathways for development and partnering. The publication enhances the visibility and scope of Genflow's IP estate at an international level. It supports the Company's strategy of building layered protection around the therapeutic use of SIRT6 variants across multiple age-related indications. The PCT publication also preserves Genflow's ability to pursue patent protection across multiple jurisdictions, supporting development flexibility and potential discussions with pharmaceutical and biotech partners. Taken together, this publication reinforces the depth of the Company's scientific platform and the continued expansion of its intellectual property backbone. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Annuncio • Apr 10
Genflow Biosciences plc Reports Sustained Safety and Efficacy Three Months Post Dosing in Slab Trial Genflow Biosciences Plc highlighted continued positive safety and efficacy signals from its ongoing SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy. Follow-up observations conducted three months after the initial dosing period confirm that previously reported improvements have been maintained. No adverse events have been observed, and the therapy continues to demonstrate a favourable safety and tolerability profile in aged dogs. These findings build on the Company's previously announced interim results and provide early evidence supporting the durability of the therapy's effects. Improvements across multiple independent endpoints remain consistent with earlier observations, while control animals continue to exhibit expected age-related decline. The SLAB study remains ongoing, with all dogs continuing to be actively monitored and evaluated. The trial is expected to continue for a further four months, with completion anticipated at the end of July 2026. Additional analyses, including methylation clock (biological age) assessment and muscle histology, are in progress and are expected to provide further mechanistic and quantitative insight into the therapy's impact. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Annuncio • Mar 06
Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.8 million. Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,105,263
Price\Range: £0.019
Security Features: Attached Warrants Annuncio • Mar 03
Genflow Biosciences plc Confirms Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development Genflow Biosciences Plc confirmed receipt of the first instalment of €336,467 of the previously announced €4 million non-dilutive grant awarded by the Wallonia Region of Belgium. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap for GF-1002 in MASH. The grant will support the continued development of the Company's lead gene therapy candidate, GF-1002, with further instalments expected to be received in accordance with the agreed milestone and disbursement schedule. The first instalment has been received and will be applied toward eligible project-related activities. Annuncio • Feb 13
Genflow Biosciences plc Announces Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs Genflow Biosciences Plc announced positive preliminary interim results from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy in aged dogs. Trial overview The randomised, blinded study, conducted by an independent contract research organisation, enrolled 24 beagle dogs aged over 10 years who were allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort, and a control group. The interim analysis reflects outcomes observed during the dosing period. Additional endpoints remain under assessment. All treatment groups demonstrated superior survival compared to the control group during the dosing period. No adverse events were observed, and all treatment modalities exhibited a favourable safety and tolerability profile suitable for use in aged companion animals. Across treatment cohorts, improvements were observed in several functional and observable endpoints, including quality of life, muscle mass preservation, frailty index reduction, and coat quality, relative to control animals, which exhibited expected age-related decline. Ongoing analyses Several key endpoints remain under evaluation, including biological age determination using methylation clock analysis and comprehensive muscle biopsy histology. Annuncio • Jan 19
Genflow Biosciences plc Announces Appointment of Gad Berdugo as Independent Non-Executive Chairman Genflow Biosciences Plc announced a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: Co-Founder & CEO, EpiVax Oncology; Vice-Chairman of the Board, Evexta Bio; Chief Business Officer, Editas Medicine; Chief Business Officer, Nutcracker Therapeutics. He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Annuncio • Oct 24
Genflow Biosciences plc Announces Publication of Second European Patent Application - SIRT6 Variant for NASH Genflow Biosciences Plc announced that its second European patent application (Application No. 23821586.7, Publication No. EP4630038) titled "SIRT6 Variant for NASH" has been published in the European Patent Bulletin ("EPO"). Publication of the patent application in the European Patent Bulletin follows entry into the European phase under the Patent Cooperation Treaty (PCT) and represents a key milestone in Genflow's expanding intellectual property (IP) portfolio. This publication confers provisional protection under Article 67(3) of the European Patent Convention (EPC), enabling Genflow to claim retroactive damages in designated EPC states for infringing acts occurring after the publication date, once the patent is formally granted and national validation requirements are met. This development marks continued progress in Genflow's comprehensive patent strategy to strengthen protection for its SIRT6 gene variant technologies and expand their therapeutic reach across metabolic and age-related disorders, including NASH (non-alcoholic steatohepatitis). It also reinforces Genflow's IP leadership in the longevity and metabolic disease space, complementing the recently published EP4338267 covering the Company's core SIRT6 variant for healthy aging. Together, these filings establish a robust European patent framework supporting Genflow's therapeutic platform and upcoming clinical programs. New Risk • Oct 14
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 41% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Negative equity (-UK£303k). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (UK£9.87m market cap, or US$13.1m). Annuncio • Oct 04
Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.34 million. Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.34 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 40,000,000
Price\Range: £0.0085 Annuncio • Aug 18
Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported Genflow Biosciences Plc provided an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026. The strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment. Study objectives are to: Confirm feasibility of GF-1004 administration in the target population. Validate safety and efficacy at the proposed administered dose. Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including: Reduced biological age (GRIM methylation clock); Increased muscle strength and mass; Enhanced mitochondrial function; Improved coat quality; Better overall health metrics; Translational Potential; Since dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics. Annuncio • Jul 25
Genflow Biosciences plc Reports Key Preclinical Activities in Two of Its Lead Programs Genflow Biosciences Plc reported key preclinical activities in two of its lead programs. GF-1002 In preparation for a submission for European Clinical Trial Authorisation (CTA), the EU's regulatory equivalent to the U.S. FDA's IND process, Genflow is continuing to advance key development activities. To support this process, the Company has initiated Chemistry, Manufacturing, and Controls (CMC) work in collaboration with its CDMO partner, Exothera, to ensure clinical supply production meets Good Manufacturing Practice (GMP) standards. In parallel, pivotal efficacy studies are underway with Genflow's independent CRO partners, Physiogenex and Accelera, evaluating GF-1002 in both early and advanced stages of MASH. GF-1004 Genflow has submitted a first protocol amendment to its ongoing proof-of-concept clinical trial in aged dogs to clarify the administration of its investigational product, GF-1004. The amended protocol now specifies the intravenous (IV) dose rate to ensure consistent and controlled delivery, minimizing the risk of infusion-related adverse events and reinforcing patient safety. This randomized, controlled trial initiated in March in collaboration with the renowned CRO, Syngene is designed to evaluate the safety and efficacy of Genflow's proprietary SIRT6-centenarian gene therapy in addressing age-related decline in dogs. New Risk • Jul 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£403k). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£3.63m market cap, or US$4.91m). Minor Risk Shareholders have been diluted in the past year (30% increase in shares outstanding). New Risk • Jun 02
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 30% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£403k). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£3.86m market cap, or US$5.19m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (30% increase in shares outstanding). Annuncio • May 23
Genflow Biosciences plc, Annual General Meeting, Jun 12, 2025 Genflow Biosciences plc, Annual General Meeting, Jun 12, 2025. Location: 1 heddon street, w1b 4bd, london United Kingdom New Risk • May 02
New major risk - Negative shareholders equity The company has negative equity. Total equity: -UK£403k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£403k). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£4.01m market cap, or US$5.33m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change). New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (UK£598k revenue, or US$795k). Market cap is less than US$10m (UK£3.58m market cap, or US$4.76m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Annuncio • Apr 10
Genflow Biosciences plc Launches New Ophthalmology Development Program Genflow Biosciences Plc announced the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma. This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT 6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system. Annuncio • Mar 28
Genflow Biosciences plc has filed a Follow-on Equity Offering in the amount of £0.434084 million. Genflow Biosciences plc has filed a Follow-on Equity Offering in the amount of £0.434084 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 36,579,429
Price\Range: £0.0105
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,761,905
Price\Range: £0.0105
Transaction Features: Subsequent Direct Listing New Risk • Dec 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (UK£598k revenue, or US$749k). Market cap is less than US$10m (UK£6.12m market cap, or US$7.67m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). New Risk • Jul 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.17m (US$9.27m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£7.17m market cap, or US$9.27m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). Annuncio • Jun 27
Genflow Biosciences plc Announces Strengthening of Pre-Clinical Efforts Genflow Biosciences plc report advancements in its pre-clinical programs. Genflow has initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP). Genflow is also in the process of selecting Contract Research Organizations (CROs) to conduct its upcoming dog clinical trial, aimed at studying its promising drug candidate, GF-1004. The Company is currently evaluating requests for proposals (RFPs) and is working diligently to finalize a definitive agreement next month. In addition, Genflow has received research guidance from the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT). The Company submitted a comprehensive briefing package detailing all preclinical (in vitro and in vivo) studies conducted with its lead drug candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH). The FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept (POC) studies. These studies will inform the definitive POC, toxicology, and biodistribution studies necessary for eventual clinical trials. Detailed summaries of the products used in each animal study and their comparability to the intended clinical product are to be included. Annuncio • Jun 05
Genflow Biosciences plc, Annual General Meeting, Jun 27, 2024 Genflow Biosciences plc, Annual General Meeting, Jun 27, 2024. Location: 1 heddon street, w1b 4bt, london United Kingdom New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (UK£194k revenue, or US$242k). Market cap is less than US$10m (UK£5.68m market cap, or US$7.07m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (20% increase in shares outstanding). Annuncio • Apr 04
Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.715 million. Genflow Biosciences plc has completed a Follow-on Equity Offering in the amount of £0.715 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 57,200,000
Price\Range: £0.0125
Security Features: Attached Warrants
Transaction Features: Subsequent Direct Listing New Risk • Jan 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m (UK£194k revenue, or US$246k). Market cap is less than US$10m (UK£6.29m market cap, or US$7.99m). Annuncio • Jan 18
Genflow Biosciences plc Announces Two Non-Dilutive Research Grant Awards Genflow Biosciences PLC announced Two Non-Dilutive Research Grant Awards. The Company announced two significant new research programs in collaboration with Revatis SA and EXO Biologics, backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Funding for the two research programs, as part of the Wallonia Recovery Plan by the Walloon Government in Belgium, will be disbursed annually to the Company, contingent upon Genflow and its collaborators achieving specific, activity-based milestones. Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year. The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region. Genflow, together with Revatis SA, has launched a 3-year sarcopenia research program, generously funded by a grant totalling 1.34 million euros. Sarcopenia, the progressive loss of muscle mass and function associated with ageing, poses a significant health risk and affects the quality of life for millions of elderly people worldwide. This collaborative effort aims to expand and diversify Genflow's research pipeline, addressing this growing concern as the global population ages. The partnership will leverage both companies' expertise to develop innovative solutions and contribute valuable insights into the mechanisms of age-related muscle deterioration. Genflow and EXO Biologics have initiated a 3-year scientific program, supported by a grant of 1.55 million euros. The project focuses on the development of a novel mRNA delivery system using exosomes to encapsulate and transport Genflow's proprietary centenarian SIRT6 gene. This cutting-edge approach aims to harness the natural advantages of exosomes, such as enhanced stability, improved cellular uptake, reduced immunogenicity, minimal toxicity, natural cargo sorting and reduced off-target effects, among others. This endeavour not only demonstrates Genflow's momentum in leading-edge research, but also holds the potential to revolutionize therapeutic interventions for Werner Syndrome, an accelerated ageing condition and holds great promised for a range of other age-related conditions. Annuncio • Sep 20
Genflow Biosciences Plc Announces Company Update Genflow Biosciences Plc announced the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium. The Company is pleased with the advice received from the FAHMP to commence clinical trials of its drug, GF-1002, with patients suffering from NASH (rather than in healthy volunteers). This follows promising results from the Company's research in in-vitro human cells and in-vivo rodent studies. The Company's NASH clinical trials are scheduled to begin in approximately 18 months following dialogue and subsequent agreement with the European Medicine Agency. Annuncio • May 17
Genflow Biosciences plc, Annual General Meeting, Jun 08, 2023 Genflow Biosciences plc, Annual General Meeting, Jun 08, 2023, at 08:00 Coordinated Universal Time. Location: Westend Corporate LLP,6 Heddon Street London United Kingdom Annuncio • May 12
Genflow Biosciences plc Announces Appointment and Internal Restructure Genflow Biosciences plc announced that In light of the ongoing progress being achieved by Genflow, the Board of Directors has proactively decided to restructure both itself and the Company's Scientific Advisory Board ("SAB"). This step has been taken to align with the Company's current objectives and priorities in the US, including the OTCQB application previously announced, as outlined below: Tamara Joseph, the Company's US-based Non-Executive Director, has been promoted to Chairperson of the Board. Her experience in financing, coupled with her familiarity with the US public markets, will play a crucial role going forward. Tamara has an impressive track record in public and private financings, having supported Nasdaq financings in excess of $800m. Her expertise in the field of finance is further strengthened by her academic credentials, which include a JD from the University of Michigan Law School and LLM degrees from the College of Europe in Belgium and the University of Paris. Having served as an adviser to the boards of five US publicly traded biotechs, Tamara has demonstrated a strong ability to lead companies. Her promotion is a recognition of her expertise and strengthens the Company's links with the US market. YassineBendiabdallah, will remain a key member of the Board and will continue to act as a Non-Executive Director. Vera GorbunovaPhD,has been promoted to Chairperson of the SAB. Dr Gorbunova is an endowed Professor of Biology at the University of Rochester, New York, and Co-Director of the Rochester Ageing Research Center, where her research focuses on the mechanisms of longevity and genome stability, as well as studies on exceptionally long-lived mammals. Throughout her career, Dr. Gorbunova has received numerous awards for her work, including from the Ellison Medical Foundation, the Glenn Foundation, the American Federation for Ageing Research, and the National Institutes of Health. Her research has also been recognized with the Cozzarelli Prize from PNAS, the prize for research on ageing from ADPS/Alianz (France), the Prince Hitachi Prize in Comparative Oncology (Japan), and the Davey Prize from Wilmot Cancer Center. As Chairperson of the SAB, Dr. Gorbunova's outstanding contributions to the field of longevity and her invaluable insights in this sector will be instrumental in guiding the Company's scientific research. This appointment is a testament to her expertise and achievements in the field. Dr Eric Verdinwill remain a key member of the SAB. Professor Dr Sven Francque is joining the SAB. Professor Francque is a renowned expert in the field of nonalcoholic fatty liver disease (NAFLD) and its advanced form, nonalcoholic steatohepatitis (NASH). He has a long-standing interest and expertise in NAFLD and NASH, with research focusing on the vascular changes in steatosis and their contribution to disease progression. Genflow stands to gain significant value from Professor Francque's extensive knowledge of NASH, particularly in identifying new targets and potential therapies for the disease. Moreover, Professor Francque's expertise in clinical research and clinical trial design will be invaluable in the development of clinical trial programs for the Company's novel therapeutics. His membership on the SAB will play a vital role in shaping and broadening the Company's strategy and direction, and his vast experience will be integral to achieving the Company's goal of improving the lives of patients with NAFLD and NASH. Board Change • Mar 31
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. No highly experienced directors. Founder, CEO & Executive Director Eric Leire is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Jan 19
Genflow Biosciences plc has completed an IPO in the amount of £3.76292 million. Genflow Biosciences plc has completed an IPO in the amount of £3.76292 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 47,036,500
Price\Range: £0.08
Transaction Features: Direct Listing; Regulation S Board Change • Jan 18
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
